The upregulation of METTL14 has been demonstrated to lead to the decrease of PERP level through m6A modification which promotes the metastasis and growth of pancreatic cancer; thus, METTL14 can be a potential therapeutic target for pancreatic cancer31. Here, PERP is linked to familial pancreatic carcinoma.